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orphogenesis of a vascular network requires
dynamic vessel growth and regression. To in-
vestigate the cellular mechanism underlying
this process, we deleted focal adhesion kinase (FAK), a
key signaling mediator, in endothelial cells (ECs) using
Tie2-Cre mice. Targeted FAK depletion occurred efﬁ-
ciently early in development, where mutants exhibited a
distinctive and irregular vasculature, resulting in hemor-
rhage and lethality between embryonic day (e) 10.5 and
11.5. Capillaries and intercapillary spaces in yolk sacs
were dilated before any other detectable abnormalities at
e9.5, and explants demonstrate that the defects resulted
M
 
from the loss of FAK and not from organ failure. Time-
lapse microscopy monitoring EC behavior during vascu-
lar formation in explants revealed no apparent decrease
in proliferation or migration but revealed increases in cell
retraction and death leading to reduced vessel growth
and increased vessel regression. Consistent with this phe-
notype, ECs derived from mutant embryos exhibited aber-
rant lamellipodial extensions, altered actin cytoskeleton,
and nonpolarized cell movement. This study reveals that
FAK is crucial for vascular morphogenesis and the regu-
lation of EC survival and morphology.
 
Introduction
 
Mouse vascular morphogenesis begins in the yolk sac (YS) on
embryonic day (e) 6.5, when endothelial cells (ECs) differentiate
from mesenchymal-derived precursors (angioblasts) in the blood
islands of the extraembryonic mesoderm. ECs subsequently coa-
lesce into a honeycomb-shaped primitive capillary plexus. This
de novo formation of blood vessels is called vasculogenesis and
occurs slightly later in the embryo proper. By e8.5, the dorsal
aortae, cardinal veins, and the surrounding primitive vascular
plexus emerge. To assemble a mature vascular network com-
posed of a hierarchy of arteries, arterioles, capillaries, postcapil-
lary venules, and veins, the primitive vasculature undergoes a
profound remodeling starting at e8.5 involving vessel expansion
and regression (Haar and Ackerman, 1971; Risau, 1997).
Angiogenesis, the growth of new capillaries from pre-
existing blood vessels, plays an essential role in vascular ex-
pansion (Yancopoulos et al., 2000; Rossant and Howard, 2002;
Carmeliet, 2003). Two mechanisms are involved in forming
new vascular segments. Sprouting angiogenesis is the exten-
sion of new vessels from existing capillaries into avascular tis-
sues. It is thought that tip cell migration results in a decrease in
EC-to-cell contacts, triggering EC proliferation and generation
of new blood vessels (Ausprunk and Folkman, 1977). Thus, EC
migration and proliferation are crucial events in sprouting an-
giogenesis. Intussusceptive angiogenesis is a process in which
new vessels are formed by the insertion and extension of trans-
lumenal tissue pillars. It is hypothesized that these processes
require no immediate proliferation of ECs; rather, they depend
on the rearrangement of existing cells through the regulation of
cell migration and adhesion (Burri and Djonov, 2002).
Vascular regression, or pruning, is an essential remodel-
ing process in which excess ECs or vascular segments are
eliminated to construct an efficient network (Risau, 1997). It
is believed that only a minority of blood vessels formed dur-
ing embryonic development remain through adulthood (Ri-
sau and Flamme, 1995). The two most prominent examples
of vascular regression are the primordial aortic arches and
paired dorsal aortae, which exist only transiently in mammals
(Moore and Persaud, 2003). The precise morphological
events, along with the underlying cellular and molecular
mechanisms, remain obscure.
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Targeted mutagenesis of many signaling pathways (e.g.,
VEGF, angiopoietin, ephrinB2, Notch, or TGF-
 
 
 
) results in a
defective primitive vascular network, suggesting that they are
essential for vascular remodeling (Rossant and Howard, 2002).
However, these signaling pathways often elicit an array of
biological effects, and the precise cellular function and intra-
cellular signaling events that mediate such function within ECs
are unclear.
FAK is a ubiquitously expressed protein–tyrosine ki-
nase that mediates integrin, growth factor, and mechanical
stress signaling (Miranti and Brugge, 2002; Parsons, 2003;
Schlaepfer et al., 2004). Localized to focal adhesions, it inter-
acts with integrin-associated proteins, such as paxillin and
talin, and elicits downstream signaling. Activation of FAK via
tyrosine phosphorylation occurs when cells are grown on inte-
grin ligands or are stimulated by certain growth factors. The
importance of FAK in vascular morphogenesis is evident be-
cause of its abundant expression in the vasculature at the time
of critical vascular development (Polte et al., 1994). Further-
more, 
 
fak
 
-null embryos die at e8.5 with multiple defects, in-
cluding a disorganized cardiovascular system (Ilic et al., 1995).
The presence of ECs in 
 
fak
 
 
 
/
 
 
 
 embryos indicates that the ab-
sence of 
 
fak
 
 does not prevent EC differentiation (Ilic et al.,
2003). However, 
 
fak
 
-null embryos fail to form vascular net-
works, suggesting that FAK functions in the subsequent angio-
genesis and vascular remodeling.
In vitro experiments have also demonstrated that FAK re-
lays angiogenic signaling from multiple pathways, including
those of VEGF and angiopoietin-1, and mediates EC migra-
tion, survival, and proliferation (Abu-Ghazaleh et al., 2001;
Kim et al., 2001; Maru et al., 2001; Qi and Claesson-Welsh,
2001; Orr and Murphy-Ullrich, 2004). It is well recognized that
conclusions drawn from in vitro experiments can be inconsis-
tent with in vivo findings. For example, in ECs as well as in
other cell types, FAK is critical for in vitro cell proliferation
(Gilmore and Romer, 1996; Zhao et al., 1998). However, no
change in cell proliferation was detected in 
 
fak
 
 
 
/
 
 
 
 embryos or
in a brain-specific conditional deletion mutant (Ilic et al., 1995;
Beggs et al., 2003), raising doubts about whether FAK is im-
portant for cell proliferation in vivo. Furthermore, studies in
different cell types reveal differential effects of FAK on cell
migration. For example, 
 
fak
 
-null fibroblasts exhibit an increase
in focal adhesion contacts and a decrease in cell migration (Ilic
et al., 1995; Schlaepfer et al., 1999). However, HeLa cells ex-
pressing reduced levels of FAK by short inhibitory RNA dem-
onstrate an increase in cell motility (Yano et al., 2004), raising
the possibility that FAK may elicit diverse effects in different
cell types. Thus, it is imperative to dissect FAK’s role in specific
cell lineages in an in vivo environment.
In this study, we selectively deleted 
 
fak
 
 in ECs during
mouse embryogenesis and investigated the subsequent effects on
vascular morphogenesis. We also monitored EC behavior using
time-lapse microscopy of embryonic explants and isolated pri-
mary ECs. Our work, with its comprehensive in vivo and in vitro
evidence, demonstrates that 
 
fak
 
 in ECs is required for vascular
maintenance and that its deletion severely compromised EC
survival and spreading, leading to vascular regression.
Figure 1. Cre efficiently mediates gene excision early in the vasculature
of Tie2-Cre embryos. (A and B) AP-stained embryos at e7.5 (A) and e8.5
(B) show Cre activity in blood islands (arrows) and dorsal aortae (arrow-
heads). (C) A LacZ-stained YS at e11.5. (D) Paraffin section of e11.5
LacZ-stained embryo shows Cre activity in ECs (arrowhead) and blood
cells (arrow). (E and F) FAK expression in cells from e9.5 embryos stained
with anti-CD31 (green), DAPI (blue), and anti-Y397pFAK (red, E and F) or
anti-FAK (red, E’ and F’). Bars, 10  m. (G) Cre-mediated FAK depletion
was measured by the percentage of FAK
  CD31
  cells in mutants at e8.5,
9.5, and 10.5 relative to controls. Each represents the mean   SEM (error
bars) of 100 CD31
  cells in three replicate (for anti-Y397FAK) and five
replicate (for anti-FAK) experiments. (H) Expression of FAK, Pyk2, and
FRNK by Western or IP analyses of e9.5 embryos. 
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Results
 
Tie2-Cre
 
 efficiently mediates FAK 
depletion in early vascular development
 
To delete 
 
fak
 
 in ECs, we generated vascular-specific Cre mice
using the 
 
Tie2
 
 promoter/enhancer (Schlaeger et al., 1997).
To screen and characterize the mice, we used either Z/AP or
Rosa26R reporter mice, in which AP or 
 
 
 
-galactosidase activity,
respectively, is activated only after Cre-mediated recombination
(Lobe et al., 1999; Mao et al., 1999). From nine founder lines, we
selected one that efficiently mediated gene excision. Cre was ac-
tive at e7.5 in the blood islands of the extraembryonic mesoderm
(Fig. 1 A), the earliest vascular cells, and in the dorsal aortae at
e8.5 (Fig. 1 B). At e11.5, Cre was active in all vessels examined,
including the vitelline vessels (Fig. 1 C). Histological evaluation
revealed that Cre was active in ECs along with some blood cells
(Fig. 1 D). These results demonstrated that Cre-mediated gene
excision occurred specifically in early vascular progenitor cells,
differentiated ECs, and some hematopoietic cells.
Using this Cre line, we created the conditional mutants
(called mutants in this study) 
 
Tie2-Cre; fak
 
flox/flox
 
 and 
 
Tie2-Cre;
fak
 
flox/-
 
. Littermates missing any of the required alleles were used as
controls throughout the study. In the 
 
fak
 
flox
 
 allele, two loxP sites
flank the exon encoding the second kinase domain, which results in
ablation of FAK protein expression but does not affect the expres-
sion of FAK-related nonkinase (FRNK; Beggs et al., 2003). To
verify the excision of the 
 
fak
 
flox
 
 allele and the absence of FAK ex-
pression in ECs, we stained cells isolated from embryos because in
situ identification of 
 
fak
 
-null ECs was obscured by adjacent
perivascular cells still expressing FAK. We performed double
staining with anti–P-Y397FAK (Sieg et al., 2000) and anti-CD31
(an EC marker; Newman et al., 1990). FAK was present in the fo-
cal adhesion contacts of both CD31
 
 
 
 and CD31
 
 
 
 cells (Fig. 1 E).
Although non-ECs from a mutant still expressed FAK, most
CD31
 
 
 
 cells from the mutant did not express FAK (Fig. 1 F). To
assess the time course of the 
 
Tie2-Cre
 
–mediated FAK depletion,
we quantitatively analyzed endothelial FAK expression at different
gestational stages. FAK was absent in 
 
 
 
70% of ECs at e8.5,
 
 
 
90% at e9.5, and 
 
 
 
95% at e10.5 (Fig. 1 G). Thus, the 
 
Tie2-Cre
 
–
mediated deletion of 
 
fak
 
flox
 
 began before e8.5 and resulted in the
nearly complete depletion of FAK protein in CD31
 
 
 
 cells by e10.5.
To verify the loss of FAK expression, we performed dou-
ble immunostaining with antibodies (Abs) specific to the COOH
terminus of FAK and CD31 in purified ECs from e9.5 embryos
and found similar FAK deletion (Fig. 1, E
 
 
 
–G). Furthermore, us-
ing this Ab, we examined lysates of e9.5 embryos by Western
blotting. Despite the presence of other cell types, we detected a
significant reduction in FAK expression in the mutant (Fig. 1 H),
further validating efficient 
 
fak
 
 deletion. Expression of FRNK
was low, undetectable by Western blotting (unpublished data),
and was unchanged by immunoprecipitation (IP; Fig. 1 H).
In contrast, the expression of Pyk2 (proline-rich tyrosine
kinase 2), a FAK-related kinase, was unchanged in embryonic
lysates (Fig. 1 H). We also performed triple immunostaining with
Abs to CD31, FAK, and Pyk2 and found no obvious increase in
Pyk2 signal in mutant ECs without FAK (Fig. S1, available at
http://www.jcb.org/cgi/content/full/jcb.200506184/DC1).
 
Table I. 
 
Depletion of 
 
fak
 
 in the vasculature results in hemorrhage and 
embryonic death at ~e11
Embryonic Number of embryos Mutant embryos
stage Litters Mutant/control Bleeding Alive
 
e9.5 22 35/209 (17%) 0/35 (0%) 35/35 (100%)
e10.5 15 28/141 (20%) 28/28 (100%) 22/28 (90%)
e11.5  5 4/49 (8%) NA
 
a
 
0/4 (0%)
 
a
 
Not applicable.
Figure 2. Tie2-Cre–mediated FAK depletion causes hemorrhaging and
vascular defects at e10.5. (A and B) Images of freshly dissected YSs (A)
and embryos (B). Arrow, bleeding; diamonds, dilated sinusoidal vessels;
asterisk, heart; arrowheads, major vessels. Bars, 1 mm. (C and D) Micro-
angiographs of CD31-stained YSs. Note that only the remnants of large
vessels are identifiable in the mutant (D, arrows). (E and F) Microangio-
graphs of CD31-stained heads. Arrowheads, internal carotid artery. Note
the abnormally wide irregular vessels in the mutant. Bars, 200  m. 
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Deletion of 
 
fak
 
 disrupts the vasculature, 
leading to hemorrhage and death at 
e10.5–11.5
 
Because FAK is deleted in early development, we predicted
that our mutants would die early in gestation from lethal
vascular defects. However, at e9.5, no detectable gross ab-
normalities were observed (Table I and unpublished data).
At e10.5, 
 
 
 
10% of the mutants were dead, and the remain-
ing live mutants were readily identified by severe vascular
defects. At e11.5, no live mutant embryos were recovered
(Table I).
To determine the embryonic phenotype more precisely, we
examined the mutant embryos at e10.5. The mutant YSs lacked
the blood-filled vascular tree typically observed in the controls.
Instead, hemorrhage was apparent in both the amniotic and YS
cavities (Fig. 2 A). Although major structures were present in the
embryo proper, the mutants were slightly smaller and showed
patches of sequestered blood (reflecting dilated vessels) primarily
in the upper trunk and head regions (Fig. 2 B).
To examine any endothelial abnormalities, we performed
whole-mount immunostaining using anti-CD31 and found
abundant CD31
 
 
 
 ECs organized in severely defective vascular
structures. The mutant YSs lacked the hierarchical vitelline
vascular pattern seen in the controls (Fig. 2 C), and only rem-
nants of major vessels were observed (Fig. 2 D). The mutant
capillary plexuses lacked the intricate network structure seen in
the controls; instead, the microvessels were irregularly shaped,
frequently dilated, and flattened with a sheetlike appearance
and thin, spiky connections (Fig. 2 D and not depicted). We ob-
served a distinct internal carotid artery that was well connected
to a homogenous network of head capillary plexuses in the
control (Fig. 2 E) but not in the mutants. Instead, as in the mu-
tant YS, vessels appeared flat and fused to the surrounding
widened and sinusoidal capillaries, leading to a great variation
in the size of the capillaries and intercapillary spaces (Fig. 2 F).
 
Sprouting angiogenesis is absent in the 
neuroepithelium (NE)
 
Because the NE lacks mesenchymal cells, its vascularization is
dependent entirely on the invasion of vessel branches gener-
ated from preexisting vessels in the surrounding tissues by
sprouting angiogenesis (Kurz et al., 1996). We observed a
complete absence of blood vessels in the NE at e10.5 by CD31
staining, indicating that the 
 
fak
 
-null mutants were defective in
sprouting angiogenesis into the NE (Fig. 3).
Figure 3. Impaired sprouting angiogenesis into the NE in e10.5 mutants.
(A and B) Paraffin cross sections of the apical head stained for CD31
(brown). Note multiple small perineural plexus (PP) capillaries in the NE in
the control (A) but not in the mutant NE (B). (C and D) 100- m cross sections
of the heads show the capillary network in the control NE (C) but not in the
mutant (D). Brackets, width of the NE. Bars, 100  m.
Figure 4. e9.5 mutants display no gross defects in major vascular structures. (A–D) Microangiographs of e9.5 YSs stained with Abs to CD31 (green, A and B)
and SM A (red, C and D). (E–H) Microangiographs of whole-mount (E and F) and thick-sectioned (G and H) embryos labeled with Abs to CD31 and
SM A. Arrows, dorsal aortae; black arrowheads, aortic arches; asterisks, heart chambers; white arrowheads, paired cardinal veins. Bars, 200  m. 
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Vascular defects are the earliest 
detectable abnormalities
 
Because major vessels were severely defective at e10.5, we
questioned whether they had never developed or had degener-
ated. To distinguish between these possibilities, we analyzed
the vasculature at e9.5 by CD31 and smooth muscle 
 
 
 
-actin
(SM
 
 
 
A) double immunostaining. At e9.5, the mutant embryos
were morphologically indistinguishable from the controls
when viewed under a dissecting microscope (unpublished
data). The appearance of mutant YS vasculature was surpris-
ingly similar to that of controls, with comparable branching
patterns and recruitment of smooth muscle cells, except that the
vitelline arteries were slightly less elaborate (Fig. 4, A and B).
Staining for SM
 
 
 
A revealed that smooth muscle cells were re-
cruited to vitelline arteries in both the controls and mutants
(Fig. 4, C and D).
In the e9.5 embryo proper, CD31 and SM
 
 
 
A double
staining revealed no apparent differences between the head
vasculature of the mutants and the controls (unpublished data).
In addition, the major embryonic vessels (including the dorsal
aortae, aortic arches, and cardinal veins) and cardiac chambers in
the mutants had developed comparably (Fig. 4, E and F). To fur-
ther verify these findings and to examine vessels that were not
visible on the surface, we analyzed 100-
 
 
 
m–thick cross sections
of CD31-stained embryos (Fig. 4, G and H), finding again that
the dorsal aortae and cardinal veins were comparable. However,
we noticed fewer small vessels in the mutant cross section (Fig.
4 H), suggesting that vascular defects had begun to develop.
Given that 
 
Cre
 
 is also expressed in hematopoietic cells in
 
Tie2-Cre
 
 mice, we looked for defects in blood cells. Upon
gross examination, blood was present in e9.5 mutant embryos
and YSs, similar to the controls. Furthermore, we isolated e9.5
circulating hematopoietic cells and found no significant differ-
ence in the number of cells isolated from the controls and mu-
tants (unpublished data). This result suggests that no obvious
hematopoietic abnormalities had developed at this stage. Alto-
gether, these phenotypic findings at e9.5 indicate that subtle
vascular defects had begun to develop and that they are primary
effects of the loss of FAK in ECs.
 
Dilated capillaries and intercapillary 
spaces are primary defects
 
To identify the cellular defects during vascular development,
we focused on the highly reproducible irregular microvessel
sizes seen in the e10.5 mutant YSs. To investigate this pheno-
type further and to avoid any secondary effects that might
have contributed to it, we examined the mutants at e9.5, before
other detectable abnormalities. High magnification micro-
angiographs of mutant YSs showed wider capillary diameters,
fewer small intercapillary spaces, and larger intercapillary
areas that were often associated with incomplete vascular
sprouts (Fig. 5, A and B). To confirm these observations quan-
titatively, we analyzed the YS microangiographs morphomet-
rically. The mutant YSs had a 10-
 
 
 
m (25%) increase in mutant
capillary width that was accompanied by a reduction in the
number of intercapillary areas smaller than 200 
 
 
 
m
 
2
 
 and an in-
creased number of intercapillary spaces that were larger than
2,000 
 
 
 
m
 
2
 
 in diameter (Fig. 5, G and H). Branch points repre-
senting network complexity were significantly reduced in the
mutants (Fig. 5 I).
To separate any influence of the heart, blood, or other or-
gans that might contribute to the vascular phenotype, we ana-
lyzed capillary morphogenesis in embryonic explants ex vivo.
Figure 5. Dilated capillaries and intercapillary spaces are primary defects.
(A and B) Microangiographs of e9.5 control (A) and mutant (B) YSs. Note
fewer small intercapillary spaces (arrows), widened capillaries (asterisk),
and more incomplete sprouts (arrowheads) in the mutant. Bars, 100  m.
(C and D) Microangiographs of control (C) and mutant (D) allantoic ex-
plants. Arrowheads, widened intercapillary spaces. Bars, 200  m. (E and F)
Microangiographs of control (E) and mutant (F) P-Sp explants. Note a re-
duction in network complexity and wider vessels in the mutants. (G–L)
Quantification of capillary diameters, intercapillary space sizes, and number
of branch points in YSs (G–I) and allantoic explants (J–L). Error bars
represent SEM. *, P   0.05. 
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Microangiography of allantoic explants (Fig. 5, C and D) and
para-aortic splanchnopleural mesoderm (P-Sp) explants (Fig. 5, E
and F) revealed vascular phenotypes similar to those in the YSs.
Dilation of capillaries and intercapillary spaces was observed
along with a reduction in network complexity. A quantitative as-
sessment revealed an approximate threefold increase in capillary
width, which is a significant reduction in intercapillary spaces
 
 
 
200 
 
 
 
m
 
2
 
, an increase in intercapillary spaces 
 
 
 
2,000 
 
 
 
m
 
2
 
, and
a reduction in the number of branch points (Fig. 5, J–L). Because
the explant phenotypes resembled the in vivo capillary defects,
they likely represent the primary effects of 
 
fak
 
 deletion in ECs.
 
Reduced vessel growth and increased 
vessel regression and contraction in 
mutant explants
 
To identify defects in vascular development, we performed time-
lapse microscopy on P-Sp explants carrying an additional 
 
Tie1-
GFP
 
 allele in which GFP is driven by an EC-specific promoter
(Iljin et al., 2002). Because the P-Sp explants were taken from
e8.5–9.5 embryos, most ECs had lost FAK. To ensure that Cre
was active, we used the Rosa26R reporter and confirmed that
explant vascular networks were positive for Cre activity (un-
published data). The most striking differences involved vessel
contraction. The control explants (Fig. 6, A and B; and Video 1,
available at http://www.jcb.org/cgi/content/full/jcb.200506184/
DC1) retained a high level of network integrity. In contrast, the
mutant explants (Fig. 6, C and D; and Video 2) underwent a
process in which ECs contracted and clustered with each other,
resulting in an irregular network composed of wider and smaller
vessels, which is reminiscent of the e10.5 YS microvessels.
In addition, we analyzed endothelial sprouts and net-
works in 286 videos and found apparent vessel deterioration:
51.8% of mutant vessels regressed versus 30.1% of control
sprouts, and 51.1% of mutant networks regressed versus 18.8%
Figure 6. Still images of capillaries in P-Sp explants. Control (A) and
mutant (C) explants show comparable capillary networks at 0 h, but at
24 h, there were fewer, wider vessels in the mutant (D) compared with
the control (B).
 
Table II. 
 
Vascular morphogenesis in P-Sp explants
Frequency
Phenotype
T
 
start
a
 
 
 
→
 
 T
 
observed
 
Control
 
b
 
n
 
 (%)
Mutant
n (%)
Sprout → growth
c 58 (56.3) 40 (35.1)
Sprout → no change 14 (13.6) 15 (13.2)
Sprout → regression
d 31 (30.1) 59 (51.8)
Subtotal 103 (100) 114 (100)
Network → growth
e 39 (45.9) 22 (23.9)
Network → no change 30 (35.3) 23 (25.0)
Network → regression
d 16 (18.8) 47 (51.1)
Subtotal 85 (100) 92 (100)
aThe subcategories were defined as the phenotype at the initial point of time-
lapse videos (Tstart). The videos were captured at 10-min intervals for 24–48 h.
bControls: Tie2-Cre;fak
flox/  or fak
flox/ ; mutants: Tie2-Cre;fak
flox/flox.
cElongation, widening, and network formation from sprouts.
dReduction in length or size and degeneration, including cell death.
eIncreased network complexity and caliber.
Figure 7. Increased death in FAK-deficient ECs. (A) EC death in P-Sp
explants as detected by time-lapse microscopy. (B) Cross sections of immuno-
fluorescent  stained e9.5 YSs. Red, CD31; green, TUNEL; arrowheads,
TUNEL
  ECs. Bars, 10  m. (C) Apoptotic rate of ECs in the YSs. Bar
graph represents the mean   SEM (error bars) from three independent ex-
periments. A total of 10,175 control and 7,878 mutant ECs were
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of control networks (Table II). Furthermore, sprout and net-
work growth was reduced in the mutants (35.1 vs. 56.3% and
23.9 vs. 45.9%, respectively; Table II). Together, these results
suggest that ECs lacking FAK lead to reduced vessel growth
and increased vessel regression.
FAK deletion in ECs results in increased 
death and no significant change in 
proliferation
To determine the cellular mechanism of the vascular defects,
we analyzed cell survival, proliferation, and migration. We
monitored 4,240 control and 3,895 mutant ECs in P-Sp ex-
plants over 8 h by time-lapse microscopy. The percentage of
dying cells in the mutants was more than double that in con-
trols (5.8 vs. 2.4%; Fig. 7 A). To examine whether there was a
differential effect in sprout tip versus nontip cells, we moni-
tored 78 control and 108 mutant tip cells. Again, the overall
percentage of dying cells in the mutants was more than double
that of controls (21.8 vs. 8.6%). To verify EC apoptosis in vivo,
we performed TUNEL along with CD31 staining on YS sec-
tions, which contain fewer cell types and allow for a clearer
identification of ECs. We detected apoptotic ECs in both con-
trols and mutants (Fig. 7 B), but quantitative analysis revealed
a twofold increase in apoptotic ECs in the mutants (Fig. 7 C).
We did not detect any significant changes in EC prolifer-
ation in the explants (Fig. 8 A). To confirm this result, we
quantified EC proliferation in vivo by injecting BrdU into
pregnant mice. Cells were subsequently isolated from e9.5
embryos. The number of BrdU
  CD31
  cells was slightly, but
insignificantly, reduced in the mutant, whereas the number of
BrdU
  CD31
  cells remained the same (Fig. 8 B). Therefore,
the loss of fak did not provoke significant change in EC prolif-
eration but reduced EC survival, which is likely responsible for
the reduced vascular growth and increased vascular regression.
No reduction in cell migration in 
FAK-null ECs
To investigate EC migration in the context of vessel morpho-
genesis, we examined ECs lining the vessels in P-Sp explants.
We monitored the migration path of ECs over a 300-min period
at 30-min intervals. From 13 control and 16 mutant ECs ana-
lyzed, six representative pairs are shown in Fig. 9 A, demon-
strating no obvious difference. We quantified the velocity
(distance/interval) of 33 control and 55 mutant ECs that were
analyzed over a period of 8 h and found an average velocity of
10.7   8.7  m versus 12.2   11.56  m, respectively, indicat-
ing no major difference in the migration distance of mutant ECs
within a vessel and a subtle, insignificant increase in velocity.
Because previous reports of cell migration of FAK-deficient
cells were analyzed in isolated cells and not in an organ context
(Ilic et al., 1995; Yano et al., 2004), we examined ECs that did
not belong to a vessel structure but were scattered in the P-Sp
explants. The migration paths of six representative pairs from
Figure 8. Insignificant decrease in proliferation in FAK-deficient ECs.
(A) EC proliferation in P-Sp explants as measured by time-lapse micros-
copy. (B) EC proliferation measured by in vivo BrdU labeling. Each bar
represents the mean   SEM (error bars) of 100 cells in three independent
experiments. Control, white bars; mutant, black bars.
Figure 9. Migration paths of individual FAK-
deficient ECs in P-Sp explants. Each point indi-
cates the position (XY coordinates) of the cell
at 30- (A, capillary ECs) or 28- (B, single ECs)
min intervals. Positions of 10 consecutive inter-
vals are shown. Each axis tick represents a
distance of 10  m.JCB • VOLUME 172 • NUMBER 1 • 2006 158
26 control and 34 mutant ECs analyzed at 28-min intervals
over a 280-min period are shown in Fig. 9 B, demonstrating
an increase in cell migration of the mutant ECs. Consistent
with this result, the average velocity of 10 control and 15 mu-
tant ECs analyzed over an 8-h period was 7.6   6.6  m versus
16.7   12.8  m, respectively.
We also monitored (at 10-min intervals over 8 h) the mi-
gration of isolated embryonic ECs, which were identified by
DiI-Ac-LDL uptake or Tie1-GFP, grown on fibronectin (FN).
Control ECs exhibited extensive membrane ruffling and lamel-
lipodia formation at the migrating front (Fig. 10 A and Video 3,
available at http://www.jcb.org/cgi/content/full/jcb.200506184/
DC1). In contrast, mutant ECs were poorly spread and lacked
membrane ruffling and lamellipodia formation (Fig. 10 B and
Video 4). Spiky, thin cell protrusions extended at the cell pe-
riphery in a random fashion, compromising cell polarity.
Neither the mutant nor the control clusters of ECs migrated a
significant distance (unpublished data). The single mutant cells
were actively moving, although they lacked the stable direc-
tional migration seen in the controls. To quantify cell migration,
we tracked the cell center and found that single mutant ECs
traveled   50% longer distances compared with the controls
(unpublished data). These results demonstrate that FAK-deficient
single ECs exhibit a defective, but faster, locomotion on FN in
the presence of serum and growth supplements.
FAK-null ECs displayed defective 
lamellipodia and cell spreading
To further identify the cellular defects resulting from FAK
depletion in ECs, we examined the actin cytoskeletal structure.
Phalloidin staining revealed typical actin stress fibers through-
out the control ECs (Fig. 10 C). FAK-deficient ECs showed
fewer and abnormal stress fibers that instead resembled cortical
actin bundles (Fig. 10 D). Because fak
 /  fibroblasts exhibit an
increased number of focal adhesion contacts (Ilic et al., 1995),
we stained our mutant ECs for paxillin, which is a component
of focal adhesion contacts and an anchor for actin filaments. In
contrast to the abundant, well-spread focal adhesions through-
out the control cells, fewer focal adhesions that were peripher-
ally confined (even aggregating together) were detected in the
mutants (Fig. 10, E and F). These results suggest that the loss
of fak leads to abnormal actin cytoskeleton structure and focal
adhesion organization in ECs.
To determine the kinetics of cell spreading, we examined
cells on FN and found a marked reduction in cell spreading at
both 2 and 20 h after plating (Fig. 10 G). To ascertain whether
this was a matrix-specific result, we plated cells on laminin
(LM)-coated and poly-L-lysine (PLL)–coated plates and found
similar defects in cell spreading (Fig. 10, H and I). Therefore,
the loss of FAK compromised EC spreading through both
ECM-dependent and independent mechanisms. In summary,
these results suggest that the loss of fak leads to abnormal cell
spreading without decreasing cell migration in ECs.
Discussion
To ascertain the cellular and molecular mechanism of vascular
morphogenesis, we deleted FAK specifically in ECs. This ge-
netic alteration leads to vascular deterioration and embryonic
lethality before e11.5. Mutant ECs exhibited reduced cell
spreading and survival, aberrant (but not reduced) migration,
and no reduction in proliferation. This work demonstrates that
FAK plays a cell-autonomous function in ECs that is essential
Figure 10. Mutant ECs display defective cell morphology and locomotion.
(A and B) Micrographs of ECs overlaid with DiI-Ac-LDL labeling (red). Mutant
ECs display thin and spiky cell protrusions (arrows). (C–F) Immunofluorescent
micrographs of actin organization (C and D) and focal adhesions (E and F)
in ECs; insets, focal adhesions. Red, CD31; green, actin (C and D) or paxil-
lin (E and F); blue, DAPI. Bars, 10  m. (G–I) Time course of EC spreading on
FN, LM, and PLL at 2 and 20 h. Each bar represents the   SEM (error bars)
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for vascular formation and maintenance, delineating cell survival
as a major EC effect of FAK in vivo.
FAK as an intracellular transducer of 
angiogenic signaling
The role of FAK in transmitting angiogenic signals in ECs has
been suggested through in vitro experiments (Orr and Murphy-
Ullrich, 2004). Studies using fak knockouts also show that fak is
required for angiogenesis in vivo (Ilic et al., 1995, 2003). How-
ever, because complete ablation deletes the fak gene in all cells,
the precise function of FAK in ECs in vivo remains unknown.
Furthermore, because fak-null embryos are defective in major
developmental processes and die at e8.5, it is uncertain whether
the vascular effect of FAK is secondary to the influence of other
cell types and organs. We selectively targeted fak using the
Tie2-Cre mice that we generated. Cre-mediated efficient recom-
bination occurred in vascular progenitor cells at e7.5, and FAK
was deleted in  90% of ECs by e9.5. Specific vascular defects
developed at e9.5, and 100% lethality occurred by e11.5. In addi-
tion, we identified similar defects in embryonic explants, sug-
gesting that the vascular abnormalities are not secondary to other
organ failure. Therefore, we conclude that FAK in ECs plays an
essential role in early vascular development.
During the revision of this manuscript, Shen et al. (2005)
reported that FAK in ECs is required for late, but not early, em-
bryogenesis. Different Tie2-Cre mouse strains that were used
are likely derived from different integration sites, and the onset
of Cre activity could be different. Shen et al. (2005) demon-
strated FAK deletion at e9.5, but it is unknown what fraction of
ECs lost FAK. If the Tie2-Cre in the Shen et al. (2005) study
was less efficient in early development, it could explain their
late embryonic phenotype. Different floxed fak alleles were
used as well. Our floxed allele targets the second kinase exon,
as in the previously published fak-null allele (Ilic et al., 1995).
Shen et al. (2005) used a floxed allele targeting the third exon.
They demonstrated that their null allele resulted in a similar
early lethality; thus, the temporal differences in the phenotype
likely result from differences in Cre efficiency, and endothelial
FAK is required for early vascular morphogenesis.
It is well recognized that proper formation of vascular
trees involves vascular pruning to remove unnecessary vascu-
lar channels (Risau, 1997). Little is known about the cellular
and molecular mechanisms involved in vascular regression.
We identify a previously unappreciated molecular mechanism
mediated by FAK signaling in the maintenance of vascular net-
works. Major vessels were established and well formed at e9.5,
but by e10.5, virtually all of the major vessels had deteriorated
in the mutants. This could have been a result of the general
health of the embryos. However, time-lapse microscopy un-
equivocally revealed vessel regression in embryonic explants,
supporting the notion that fak provides survival and stabilizing
signals to ECs, thereby sustaining vascular integrity.
Cell survival is a major function of FAK 
in ECs
Based on cell culture experiments, it has been proposed that
FAK regulates multiple effects in ECs, including cell migra-
tion, proliferation, and survival (Orr and Murphy-Ullrich,
2004; Shen et al., 2005). Reports from the complete knock-
out suggest that the loss of fak compromises migration and,
thereby, impairs angiogenesis (Ilic et al., 1995, 2003). The pre-
cise cellular function of fak in ECs during angiogenesis in vivo
remains to be elucidated. We took a conditional knockout ap-
proach combined with real-time imaging of angiogenic pro-
cesses, demonstrating cell survival as a profound effect of FAK
in ECs in vivo. No increase in apoptosis was found in fak
 / 
embryos (Ilic et al., 2003). The likely discrepancy is the detec-
tion sensitivity in the complete knockouts that die before e8.5.
We counted 10,175 control and 7,878 mutant YS ECs and
found increased TUNEL
  ECs in mutants in vivo. We also in-
vestigated cell death by time-lapse microscopy and found an
increase in EC death both at the sprout tips and in the existing
network. Thus, our data show that loss of FAK can compromise
cell survival, which could contribute to the vascular deterioration
seen in the mutant embryos.
Multiple signaling molecules have been shown to function
in EC survival. Vascular endothelial cadherin abolishes the sur-
vival signal from VEGF-A to Akt and Bcl2 (Carmeliet et al.,
1999). Raf kinase mediates survival signals in ECs from basic
fibroblast growth factor and VEGF (Alavi et al., 2003). RhoB
controls Akt trafficking and regulates EC survival in vascular de-
velopment (Adini et al., 2003). Our work demonstrates that FAK
is a signaling mediator for EC survival, suggesting that it may be
involved in one or more of these signaling pathways.
Cell proliferation is not significantly 
reduced in FAK-deficient ECs
It has been previously reported that FAK can promote cell pro-
liferation in ECs and other cell types in vitro (Gilmore and
Romer, 1996; Zhao et al., 1998). Thus, it is presumed that los-
ing FAK would result in the reduction of cell proliferation.
Shen et al. (2005) also demonstrated significant reduction in
cell proliferation in cultured ECs, in which FAK was deleted in
vitro. However, neither our in vivo BrdU and CD31 double
staining nor the time-lapse microcopy on ECs in explants
demonstrated a significant reduction in cell proliferation in
mutants. Our results are consistent with other FAK knockout
studies in which no significant change in proliferation was de-
tected in vivo (Beggs et al., 2003; Ilic et al., 1995, 2003). Thus,
our in vivo assay and organ cultures, which are more physio-
logically relevant, do not support a major function for FAK in
EC proliferation in vivo.
FAK-deficient ECs exhibit a defective but 
not reduced motility
FAK-null fibroblasts derived from fak
 /  embryos exhibit re-
duced cell motility (Ilic et al., 1995; Schlaepfer et al., 1999).
However, Yano et al. (2004) reported that HeLa cells express-
ing reduced FAK by short inhibitory RNA and FAK-null fibro-
blasts exhibit increased cell motility. Thus, FAK’s role in cell
migration remains controversial. By time-lapse microscopy,
we found that migration of FAK-deficient ECs lining the capil-
laries of the explants were indistinguishable from that of the
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the explants, and single ECs grown on FN-coated dishes mi-
grated faster than controls, although they did so unstably and
lacked direction. FAK-deficient fibroblasts also show similar
unstable, random migration (Wang et al., 2001a). Shen et al.
(2005) reported reduced cell migration in response to FN in
wound closure but not in the Boyden chamber assays. How-
ever, both assays can be influenced by cell proliferation and
death, and because their ECs exhibit reduced proliferation and
increased apoptosis, the migration defect required further vali-
dation. We believe that the organ cultures used in our studies
are more physiologically relevant and that time-lapse micros-
copy can assess cell migration without influence from cell
proliferation and death.
Our results raise alternative possibilities regarding
FAK’s motility function and present a conceptual advance
beyond the idea that losing FAK results in reduced cellular
motility and, thereby, compromises angiogenesis. Interest-
ingly, WAVE2, a protein related to Wiskott-Aldrich syn-
drome, is critical for endothelial motility and seems to have a
similar but distinct function to that of FAK. WAVE2
 /  em-
bryos also die around e10.5 with vascular defects. Reduced
vessel size and enlarged intervessel areas were also evident,
indicating typical sprouting angiogenic defects. Unlike the
FAK mutants, WAVE2 mutant P-Sp explants failed to grow a
vascular network, further suggesting that sprouting angiogen-
esis was impaired, possibly because of impaired cell migra-
tion (Yamazaki et al., 2003). Growth via sprouting, albeit re-
duced, occurs in the FAK mutant. Therefore, the loss of FAK
may not completely impair EC migration in vivo. It is fasci-
nating that there is differential motility in FAK-deficient ECs
within or outside of a vascular structure, suggesting that FAK
might differentially regulate EC migration in distinct angio-
genic processes.
FAK-deficient ECs display defective 
lamellipodia and cell spreading
Changes in cell morphology after FAK depletion are crucial in
understanding FAK’s cellular function. We have demonstrated
that FAK-deficient ECs spread poorly and lack cell polarity and
round, broad lamellipodia, extending multiple pointing protru-
sions instead. The actin cytoskeleton was disorganized and
contained reduced numbers, possibly aggregations, of focal
adhesions. These morphological characteristics are consistent
with the defects seen in primary mouse embryonic fibroblasts
and cell lines expressing reduced levels of FAK (Yano et al.,
2004). The fact that FAK is transiently localized to lamellipodia
and membrane ruffles (Hsia et al., 2003) further supports the
notion that it is important for these cellular structures. The cellular
defects also provide a morphological explanation for the increase
in cell death in these cells, as cell spreading is crucial for the sur-
vival of adherent cells (Frisch and Screaton, 2001). Compro-
mised cytoskeletal organization could likely be the reason for
their defective adhesion to substrata and spreading, which may
explain the contraction seen in the explants. Together, the
morphological defects exhibited in the FAK-deficient ECs
are consistent with the defective cell behaviors resulting in
vascular defects.
Mutant EC defects resembled those observed in cells
with abnormal Rho family kinase signaling (Hall, 1998). The
retractile behavior may result from increased Rho activity,
whereas the aberrant lamellipodial protrusion may be caused
by decreased Rac activity. Staining of phosphomyosin light
chain, a major target of Rho kinase, revealed no gross alter-
ation between the mutant and control ECs (unpublished data),
suggesting that Rho activity may not be affected. Our current
hypothesis is that Rac is a likely target of FAK in ECs, which is
consistent with findings in FAK-null fibroblasts (Tilghman et
al. 2005). However, the minimal number of ECs obtained from
e9.5 embryos precludes Western blot analyses to test this
hypothesis rigorously at the present time.
In summary, our finding that FAK is crucial for vascular
stability during vascular development suggests FAK’s role in
diseased neovascularization, such as cancer and retinopathy,
during which blood vessel growth contributes to both the
pathogenesis and treatment of the diseases. It is conceivable that
FAK might prove to be a promising target for anti-angiogenic
therapy because deleting FAK can result in vascular regression.
Materials and methods
Mice
Generation of the Tie2-Cre transgenic (Tg) mice followed a previously de-
scribed procedure (Wang et al., 2001b). Founder mice were identified by
PCR genotyping, and the line was maintained in an FVB/N background.
We crossed our Tie2-Cre mice with the fak
flox/flox and fak
 /  mice, which
were maintained in a mixed background and genotyped as described
previously (Beggs et al., 2003; Ilic et al., 1995). The Tie1-GFP mice have
been previously described (Iljin et al., 2002). All animals were treated in
accordance with the guidelines of the University of California San Fran-
cisco (UCSF) Institutional Animal Care and Use Committee.
Whole-mount LacZ and AP staining
LacZ staining was performed as previously described (Carlson et al.,
2005; Carpenter et al., 2005). For AP staining, samples were fixed in 4%
PFA overnight (o/n) and stained with BM purple according to the manu-
facturer’s instructions (Roche).
Abs
Rat anti–mouse CD31, mouse anti-Pyk2, and mouse anti-Y397 phospho-
FAK were obtained from BD Biosciences. Rabbit anti-FAK was purchased
from Upstate Biotechnology. All secondary Abs were obtained from Jack-
son ImmunoResearch Laboratories. Cy3-conjugated mouse anti–mouse
SM A and rabbit anti-FN were purchased from Sigma Aldrich. Mouse
anti-BrdU was obtained from the Developmental Studies Hybridoma Bank.
Mouse anti–mouse paxillin was obtained from Zymed Laboratories, and
AlexaFluor488-conjugated phalloidin was purchased from Invitrogen.
Cell isolation
Embryos and/or YSs from e8.5–10.5 were isolated into ice-cold PBS con-
taining 1% FBS and 100  g/ml penicillin and streptomycin and were
treated with 200 U/ml collagenase III (Worthington Biochemical Corp.) in
PBS for 15 min at 37 C. 10  g/ml DNaseI (Sigma Aldrich) was added
for the last 5 min. Cells were pelleted and plated on plates or glass cover-
slips coated with 10  g/ml FN or 5  g/ml LM for 12 h at 4 C or 0.1
mg/ml of 300-kD PLL hydrobromide for 5 min at RT and blocked with
0.2% BSA for 30 min. To purify ECs, cell pellets were resuspended in
buffer with 2  g/ml CD31 and incubated for 30 min followed by binding
to Dynabeads M450 (Dynal) for an additional 30 min at 4 C with rock-
ing. Cells were washed with buffer (0.1% BSA and 2 mM EDTA in PBS
lacking Ca
2 /Mg
2 , pH 7.4). ECs were separated using a magnet and
were plated on plates coated with 10  g/ml FN. Cells were cultured in
F-12 medium supplemented with 15% FBS, 0.1  g/ml EC growth supple-
ment (Collaborative Biomedical Products), and 100  g/ml penicillin and
streptomycin. Hematopoietic cells were dissociated by gentle mechanical
disruption of e9.5 YSs, passed through a 45- m strainer, and counted.ENDOTHELIAL FAK IS CRUCIAL FOR VASCULAR DEVELOPMENT • BRAREN ET AL. 161
EC spreading and migration analysis
ECs isolated from e9.5 YSs were identified after a 1–3-h incubation with
2.5  g/ml DiI-Ac-LDL (Biomedical Technologies). Cells were viewed with a
time-lapse imaging system (Intelligent Imaging Innovations). ECs were main-
tained in a humidified 5% CO2 mixture at 37 C. EC migration time-lapse
recording frames were taken every 5–10 min continuously for up to 24 h.
Immunofluorescent staining of whole-mount specimens
Tissues were fixed in 4% PFA o/n, washed in PBS, and incubated in
blocking solution (2% BSA plus 0.1% Triton X-100 in PBS) with primary
Abs in blocking solution. After washing with blocking solution, they were
incubated with the secondary Ab in blocking solution. All incubations
were at 4 C for 12 h with gentle rocking.
Morphometric analysis of capillary beds
Five mutant and five littermate whole-mount control YSs were stained for
CD31. Capillary images were taken in areas devoid of large vessels. 50
capillary diameters and intercapillary spaces were measured for each
sample. 12 control and 4 mutant P-Sp explants were analyzed using the
entire explant area after CD31 staining. Measurements were made with
the ruler and pencil tools of Slidebook software (Intelligent Imaging Inno-
vations). Diameters were measured from edge to edge at the point in the
vessel located equidistant from its adjacent branches.
Histology and immunohistochemistry
Histology and immunohistochemistry were performed as previously described
(Carpenter et al., 2005) using the Abs listed above.
Immunofluorescent staining of sections and isolated cells
Rehydrated paraffin sections were blocked with 5% donkey serum in PBS
for 2 h at RT and incubated with the primary Ab at 4 C o/n followed by
secondary Ab incubation for 1 h at 4 C. After being washed with PBS,
samples were mounted with Vectashield containing DAPI (Vector Laborato-
ries). Cells grown on coverslips were fixed in 4% PFA/PBS for 20 min and
permeabilized in 0.1% Triton X-100/PBS for 3–10 min at RT before block-
ing in 1% BSA for 1 h, after which the same staining procedure was used.
Cell proliferation and TUNEL assays
BrdU labeling was performed using a kit from Zymed Laboratories. BrdU
at 100  g/g body weight was injected (i.v.) into pregnant females at
gestation day 9.5 1 h before embryo collection. Cells were isolated as
described above and cultured for 3 h. BrdU was detected according to
the manufacturer’s instructions.
To examine apoptotic ECs, e9.5 YSs were fixed in 4% PFA o/n,
embedded in optimal cutting temperature, and frozen sectioned at 8 or
10   m. Apoptosis of ECs was detected by double immunofluorescent
staining for CD31 and subsequent TUNEL using a Fluorescein In Situ Apop-
tosis Detection Kit (Intergen Company). CD31
  ECs were counted, and
the ratios of TUNEL
  CD31
  to total CD31
  ECs were obtained. Statistical
analysis was performed using the t test.
Allantoic and P-Sp explants
Allantoic explants were cultured according to a previously published proto-
col (Downs et al., 1998) except that 50% FCS was used instead of 50% rat
serum. Allantoises were isolated at e8.0 at the four to six–somite stage and
cultured for 54 h on FN-coated dishes. Explants were stained with anti-CD31
as described in Immunofluorescent staining of sections and isolated cells.
For P-Sp explants, the P-Sp region of an embryo was dissected and
placed into a 12-well dish on top of a confluent OP9 stromal cell layer ac-
cording to methods described previously (Takakura et al., 1998). Explants
were cultured in RPMI 1640 medium supplemented with 10% FBS, which
was changed daily. Tie1-GFP Tg ECs were imaged as described above (in
EC spreading and migration analysis) every 5–10 min for up to 5 d.
For EC migration analyses, the XY coordinates of single ECs and capillary
ECs were tracked.
Western blotting and IP
Western blotting and IP was performed as previously described (Wang et
al. 2001b) using a polyclonal anti-FAK Ab or a polyclonal anti-Pyk2 Ab.
IP was performed to detect FRNK using a monoclonal anti-FAK Ab (clone
2A7) that targets the COOH terminus of FAK and FRNK.
Online supplemental material
EC and capillary structure dynamics were monitored in Tie1-GFP Tg control
(Video 1) and mutant (Video 2) P-Sp explants. Chemokinetics of isolated
e9.5 control (Video 3) and mutant (Video 4) YS ECs 18 h after plating on
FN is also shown. There was no obvious induction of Pyk2 expression in
FAK-null ECs (Fig. S1). Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200506184/DC1.
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